Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Comparing 3 techniques for eliciting patient values for decision making about prostate-specific antigen screening: a randomized controlled trial.

Pignone MP, Howard K, Brenner AT, Crutchfield TM, Hawley ST, Lewis CL, Sheridan SL.

JAMA Intern Med. 2013 Mar 11;173(5):362-8. doi: 10.1001/jamainternmed.2013.2651.

2.

A comparison of US and Australian men's values and preferences for PSA screening.

Howard K, Brenner AT, Lewis C, Sheridan S, Crutchfield T, Hawley S, Nielsen ME, Pignone MP.

BMC Health Serv Res. 2013 Oct 5;13:388. doi: 10.1186/1472-6963-13-388.

3.

Comparing 3 values clarification methods for colorectal cancer screening decision-making: a randomized trial in the US and Australia.

Brenner A, Howard K, Lewis C, Sheridan S, Crutchfield T, Hawley S, Reuland D, Kistler C, Pignone M.

J Gen Intern Med. 2014 Mar;29(3):507-13. doi: 10.1007/s11606-013-2701-0. Epub 2013 Nov 23.

4.

Pairing physician education with patient activation to improve shared decisions in prostate cancer screening: a cluster randomized controlled trial.

Wilkes MS, Day FC, Srinivasan M, Griffin E, Tancredi DJ, Rainwater JA, Kravitz RL, Bell DS, Hoffman JR.

Ann Fam Med. 2013 Jul-Aug;11(4):324-34. doi: 10.1370/afm.1550.

5.

National evidence on the use of shared decision making in prostate-specific antigen screening.

Han PK, Kobrin S, Breen N, Joseph DA, Li J, Frosch DL, Klabunde CN.

Ann Fam Med. 2013 Jul-Aug;11(4):306-14. doi: 10.1370/afm.1539.

6.

The importance of patient preference in the decision to screen for prostate cancer. Prostate Patient Outcomes Research Team.

Flood AB, Wennberg JE, Nease RF Jr, Fowler FJ Jr, Ding J, Hynes LM.

J Gen Intern Med. 1996 Jun;11(6):342-9.

PMID:
8803740
7.

Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial.

Evans R, Joseph-Williams N, Edwards A, Newcombe RG, Wright P, Kinnersley P, Griffiths J, Jones M, Williams J, Grol R, Elwyn G.

J Med Internet Res. 2010 Aug 6;12(3):e27. doi: 10.2196/jmir.1305.

8.

Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening.

Thomas R, Glasziou P, Rychetnik L, Mackenzie G, Gardiner R, Doust J.

BMJ Open. 2014 Dec 24;4(12):e005691. doi: 10.1136/bmjopen-2014-005691.

9.

Physician communication regarding prostate cancer screening: analysis of unannounced standardized patient visits.

Feng B, Srinivasan M, Hoffman JR, Rainwater JA, Griffin E, Dragojevic M, Day FC, Wilkes MS.

Ann Fam Med. 2013 Jul-Aug;11(4):315-23. doi: 10.1370/afm.1509.

10.

Does evidence-based information about screening for prostate cancer enhance consumer decision-making? A randomised controlled trial.

Gattellari M, Ward JE.

J Med Screen. 2003;10(1):27-39. Erratum in: J Med Screen. 2004;11(4):211.

PMID:
12790313
11.

The Role of Personalised Choice in Decision Support: A Randomized Controlled Trial of an Online Decision Aid for Prostate Cancer Screening.

Salkeld G, Cunich M, Dowie J, Howard K, Patel MI, Mann G, Lipworth W.

PLoS One. 2016 Apr 6;11(4):e0152999. doi: 10.1371/journal.pone.0152999. eCollection 2016.

12.

Shared decision making in prostate-specific antigen testing: the effect of a mailed patient flyer prior to an annual exam.

Landrey AR, Matlock DD, Andrews L, Bronsert M, Denberg T.

J Prim Care Community Health. 2013 Jan;4(1):67-74. doi: 10.1177/2150131912447074. Epub 2012 May 16.

PMID:
23799692
13.

Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions?

O'Dell KJ, Volk RJ, Cass AR, Spann SJ.

J Fam Pract. 1999 Sep;48(9):682-8.

PMID:
10498074
14.

Five-year downstream outcomes following prostate-specific antigen screening in older men.

Walter LC, Fung KZ, Kirby KA, Shi Y, Espaldon R, O'Brien S, Freedland SJ, Powell AA, Hoffman RM.

JAMA Intern Med. 2013 May 27;173(10):866-73. doi: 10.1001/jamainternmed.2013.323.

15.

Prostate-specific antigen testing: men's responses to 2012 recommendation against screening.

Squiers LB, Bann CM, Dolina SE, Tzeng J, McCormack L, Kamerow D.

Am J Prev Med. 2013 Aug;45(2):182-9. doi: 10.1016/j.amepre.2013.04.005.

PMID:
23867025
16.

Men's preferences and trade-offs for prostate cancer screening: a discrete choice experiment.

Howard K, Salkeld GP, Patel MI, Mann GJ, Pignone MP.

Health Expect. 2015 Dec;18(6):3123-35. doi: 10.1111/hex.12301. Epub 2014 Nov 10.

PMID:
25382490
17.

Prostate specific antigen testing in family practice: a cross sectional survey of self-reported rates of and reasons for testing participation and risk disclosure.

Carey M, Bryant J, Yoong SL, Russell G, Barker D, Sanson-Fisher R.

BMC Fam Pract. 2013 Dec 9;14:186. doi: 10.1186/1471-2296-14-186.

18.

The impact of informed consent on patient interest in prostate-specific antigen screening.

Wolf AM, Nasser JF, Wolf AM, Schorling JB.

Arch Intern Med. 1996 Jun 24;156(12):1333-6.

PMID:
8651843
19.

Screening for prostate cancer.

Ilic D, Neuberger MM, Djulbegovic M, Dahm P.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004720. doi: 10.1002/14651858.CD004720.pub3. Review.

PMID:
23440794
20.

A Community Jury on PSA screening: what do well-informed men want the government to do about prostate cancer screening--a qualitative analysis.

Rychetnik L, Doust J, Thomas R, Gardiner R, Mackenzie G, Glasziou P.

BMJ Open. 2014 Apr 30;4(4):e004682. doi: 10.1136/bmjopen-2013-004682.

Supplemental Content

Support Center